Coronavirus Notebook: COVAX Exceeds Vaccine Funding Target, Canada OKs Mix-And-Match Dosing
Executive Summary
In a sign of growing support for more equitable vaccine distribution, many donors have pledged either money or doses to lower-income economies. The World Health Organization has granted emergency use listing to another Chinese vaccine, and Russia’s Sputnik V is to be produced in Bahrain for the MENA region.
You may also be interested in...
Coronavirus Update: Pfizer/BioNTech Commit 500m Doses For US Donations
The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics.
Coronavirus Update: India Waives Local Trials For Vaccines
India has waived the need for local clinical trials for COVID-19 vaccines already approved in certain other countries, while the WHO has added a Chinese vaccine to its emergency use list. Meanwhile, South Korea issues new guidance for local vaccine trials and Japan gives more money to COVAX.
UNICEF Strikes Deal To Buy Russia’s Sputnik V Vaccine
A new procurement deal will add to the rollout of COVID-19 vaccines at global level. However, the leaders of the COVAX Facility say that by the end of June they will face a shortfall of 190 million doses, mainly because of the crisis in India, and are calling on wealthier countries to increase their donations.